Treatment of moderate-to-severe alopecia areata in patients over the age of 65 years with baricitinib
2
Issued Date
2024-08-01
Resource Type
ISSN
03076938
eISSN
13652230
Scopus ID
2-s2.0-85199147138
Pubmed ID
38270233
Journal Title
Clinical and Experimental Dermatology
Volume
49
Issue
8
Start Page
875
End Page
878
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical and Experimental Dermatology Vol.49 No.8 (2024) , 875-878
Suggested Citation
Tang G.T., Triwongwaranat D., Sinclair R., Joseph S., Eisman S., Rathnayake D., Varathan V., Trindade de Carvalho L., Bhoyrul B. Treatment of moderate-to-severe alopecia areata in patients over the age of 65 years with baricitinib. Clinical and Experimental Dermatology Vol.49 No.8 (2024) , 875-878. 878. doi:10.1093/ced/llae033 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/100039
Title
Treatment of moderate-to-severe alopecia areata in patients over the age of 65 years with baricitinib
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Baricitinib is a Janus kinase inhibitor that has been approved by the US Food and Drugs Administration for the treatment of severe alopecia areata (AA) in adults. However, the clinical trials that demonstrated the efficacy of baricitinib in the treatment of severe AA did not include men aged>60 years or women aged>70 years. We retrospectively assessed the efficacy and safety of baricitinib in 14 patients aged≥65 years with moderate-to-severe AA. After a mean (SD) duration of 18.5 (11.9) months, a 72% reduction in mean Severity of Alopecia Tool score from baseline was observed. Partial or complete eyebrow and eyelash hair was observed in 57% and 43% of patients, respectively. The adverse effects of baricitinib were mild. No cases of venous thromboembolism, major adverse cardiovascular events or malignancy were reported.